Biomerica Inc is engaged in the development, manufacturing, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company focuses on products for gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. The Company manages its operations as a single operating and reportable segment, which focus on the development, manufacture, marketing, and sale of diagnostic products. The majority of the company's revenue is earned from the Asia, and also has its presence in Europe, North America, Middle East and South America generating key revenue from North American Markets.
Last trade$1.29
Day change-$0.03 (-2.27%)
Day range$1.14 – $1.35
Volume13,472
Market cap$6M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$6.07M
Price / earnings
—
Price / book
1.66×
Price / sales
1.4×
EV / sales
0.77×
EV / EBITDA
-0.62×
Profitability
Earnings per share
-$1.09
Return on assets
-62.06%
Return on equity
-137.31%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
1.91×
Quick ratio
1.33×
Cash ratio
0.96×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$3.96M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for BMRA, quarterly periods
Line item
Q1 FY2027 Aug 31, 2026
Q4 FY2026 May 31, 2026
Q3 FY2026 Feb 28, 2026
Q2 FY2026 Nov 30, 2025
Q1 FY2026 Aug 31, 2025
Q4 FY2025 May 31, 2025
Q3 FY2025 Feb 28, 2025
Q2 FY2025 Nov 30, 2024
Revenue
$1.27M
$875K
$987K
$1.21M
$1.38M
$749K
$1.12M
$1.64M
Cost of revenue
$1.16M
$946K
$1.03M
$1.16M
$956K
$993K
$1.1M
$1.2M
Gross profit
$103K
-$71K
-$44K
$51K
$424K
-$244K
$19K
$437K
Selling, general and administrative
$1.12M
$1.26M
$1.08M
$1.23M
$1.33M
$1.07M
$1.01M
$1.17M
Research and development
$206K
$205K
$178K
$193K
$212K
$252K
$217K
$257K
Total operating expenses
$1.33M
$1.46M
$1.25M
$1.42M
$1.54M
$1.32M
$1.23M
$1.43M
Operating income
-$1.23M
-$1.53M
-$1.3M
-$1.37M
-$1.12M
-$1.56M
-$1.21M
-$993K
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$1.23M
-$1.14M
-$1.3M
-$1.32M
$5K
-$1.54M
-$1.17M
-$953K
Income taxes
$6K
$6K
$8K
$5K
$3K
$5K
-$4K
-$3K
Net income
-$1.23M
-$1.15M
-$1.31M
-$1.32M
$2K
-$1.54M
-$1.16M
-$950K
Net income attributable to common shareholders
-$1.23M
-$1.15M
-$1.31M
-$1.32M
$2K
-$1.54M
-$1.16M
-$950K
EBITDA
-$1.21M
-$1.52M
-$1.28M
-$1.35M
-$1.1M
-$1.54M
-$1.19M
-$971K
Basic earnings per share
-$0.37
-$0.37
-$0.44
-$0.45
$0.00
-$0.61
-$0.48
-$0.44
Diluted earnings per share
-$0.37
-$0.37
-$0.44
-$0.45
$0.00
-$0.61
-$0.48
-$0.44
Recent news
Company coverage with links to the original publishers.
Biomerica reported Q2 FY2026 results with net sales of $1.21M (down from $1.64M YoY) as the company transitions from legacy products to higher-margin diagnostic offerings. Key developments include a partnership with Henry Schein for inFoods® IBS commercialization, launch of an AI-backed Trigger Food Navigator tool, CMS establishment of a $300 Medicare reimbursement rate for inFoods® IBS, and Egyptian Drug Authority approval of the company's screening test portfolio. Operating expenses declined 4% YoY to $2.96M for the six-month period, and working capital improved by 14.7%.
Biomerica reported modest financial performance with $5.3 million in net sales, reduced operating expenses by $1.3 million, and improved operating loss by 19%. The company focused on strategic growth in diagnostic tests, particularly inFoods® IBS, and expanded international market presence.
The global injection molding market is projected to reach $418.39 billion by 2031, driven by growing demand from the automotive and packaging industries. Metal injection molding is expected to see the highest growth rate during the forecast period.
Biomerica reported a modest 1% increase in total revenue for fiscal year 2024, with a 5% increase in core revenue excluding COVID-19 tests. The company implemented a significant cost-savings plan and reduced its net loss by 15%. Key milestones included FDA clearance for its Hp Detect Stool Antigen ELISA test and progress in the inFoods IBS pilot program.
IRVINE, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced medical products, is proud to announce a major enhancement to its inFoods® IBS system, aimed at simplifying and transforming the patient experience.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.